GE HealthCare Technologies Inc. (GEHC)
GE HealthCare beats Q3 profit estimates on U.S. demand for medical devices
GE HealthCare Technologies beat estimates for quarterly profit on Wednesday as strong demand for its medical devices in the U.S. offset slowing sales in China due to disruptions in the country's healthcare sector because of an anti-corruption drive.
Lower Volume Likely to Hurt GE HealthCare's Q3 Earnings
GEHC's third-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line figure may reflect better pricing.
Unveiling GE HealthCare (GEHC) Q3 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for GE HealthCare (GEHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
What You Need To Know Ahead of GE HealthCare's Earnings
GE HealthCare (GEHC) is set to report earnings Wednesday morning, with analysts projecting revenue and profits to rise from the same time last year.
GEHC Stock Declines Despite the Unveiling of CareIntellect Application
GE Healthcare announces CareIntellect for Oncology to provide multi-modal patient data from disparate systems into a single view using generative AI.
GE HealthCare announces time-saving AI tool for doctors who treat cancer
GE HealthCare announced a new artificial intelligence application it said will save time for doctors who diagnose and treat cancer. The tool, called CareIntellect for Oncology, can quickly summarize patients' histories, monitor disease progression and identify relevant clinical trials, the company said.
GE HealthCare Acquires Intelligent Ultrasound's Clinical AI Business
GEHC acquires clinical AI business to aid its ultrasound portfolio with AI-driven image analysis tools.
GEHC's MIM Software to Aid Radiation Therapy With Its Latest FDA Nod
GE Healthcare's MIM Software announces the FDA clearance of Monte Carlo Dosimetry for Theranostics, enhancing precision in personalized treatment plans.
Reasons to Retain GE HealthCare Stock in Your Portfolio Now
GEHC's continued focus on innovations, acquisitions and partnerships raise optimism about the stock.
GE HealthCare Stock Likely to Rise After FDA Approval of Flyrcado
GEHC's Flyrcado, a first-of-its-kind PET tracer for coronary artery disease, receives FDA approval, expanding diagnostic access and improving patient outcomes.
US FDA approves GE HealthCare's diagnostic drug for heart disease
The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery disease, the company said on Friday.
GE HealthCare Shares Rise After AI-Powered Venue Sprint's Launch
GEHC introduces Venue Sprint, a portable AI-enabled ultrasound device offering wireless probes, real-time insights and advanced clinical tools for improved care.
